NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
Haemonetics Corporation HAE
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.3B
▼ 2.0% vs FY2024
EPS · FY25
$2.05
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
12.0%
Net margin · FY25
7.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.3B
Revenue, FY2025 · full 18-year series below
Revenue
Net income
7 cents of every revenue dollar became profit this year.
Per share
USD 2.05
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
12.0%
Return on equity, FY2025
ROE
Operating margin11.7%
Net margin7.3%
Return on assets4.0%
Each USD of equity produced 12 cents of profit this year.
Returned to shareholders
USD 175.0M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 175.0M
Share of profit179.8%
Consecutive raises—
USD 175.0M in buybacks — 180% of the year's profit, so the payout drew on cash built up earlier.
Growth
+8.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+4.5%
+8.9%
+3.9%
+4.6%
Net income
−5.5%
+4.1%
+1.3%
EPS, diluted
−2.9%
+5.8%
Returned to shareholders
+34.2%
+14.1%
+21.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years−11.0%
Change, 10 years−11.2%
The share count shrank 11% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.4B
total assets, end of FY2025
Total assetsUSD 2.4B
EquityUSD 796.3M
CashUSD 245.4M
Gross debtUSD 1.2B
Net debtUSD 979.1M
Current ratio2.95×
Net debt stands at 123% of equity.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
1.3
1.4
1.3
1.2
1.0
0.9
1.0
1.0
0.9
0.9
0.9
0.9
0.9
0.9
0.7
0.7
0.6
0.6
Operating income $B
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.1
−0.0
−0.0
0.0
0.0
0.1
0.1
0.1
0.1
0.1
EBITDA $B
0.2
0.3
0.2
0.2
0.1
0.1
0.2
0.2
0.1
0.0
0.0
0.1
0.1
0.1
0.1
0.1
0.1
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.1
0.2
0.1
0.1
0.0
0.1
0.1
0.1
0.0
−0.0
−0.1
0.0
0.0
0.0
0.1
0.1
0.1
0.1
EPS, diluted $
2.05
3.31
2.29
2.24
0.84
1.55
1.48
1.04
0.85
−0.51
−1.09
0.32
0.67
0.74
1.30
1.56
2.24
2.27
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
12.0
18.8
13.2
14.7
5.9
12.1
12.2
7.7
6.1
−3.6
−7.2
2.0
4.4
5.2
9.4
12.5
10.3
11.0
Shares out B
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.03
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
70 of 70
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed